Adnexus

TX - ZZBiotechnology

Focus: Adnexus is a newly founded (2024) biotechnology company headquartered in Texas specializing in viral-targeting antibodies. The company is at a very early stage with no disclosed pipeline, products, or financial data.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Adnexus

AI assessmentNot Hiring

No open roles listed right now. Follow Adnexus to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CT-322

Cancer

Phase 1

Clinical Trials (1)

NCT00374179CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Phase 1

Help build intelligence for Adnexus

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build a company from the ground up in a novel therapeutic area (viral-targeting antibodies) with potential for significant impact
Early-stage entry could offer equity upside and broad responsibility across functions
Emerging specialty addresses underserved viral disease space with growing clinical demand

Watch Out For

Company has zero active clinical trials, no disclosed pipeline, and no revenue—execution risk is extremely high
Founded in 2024 with no public funding data, financial position, or hiring activity disclosed—viability and runway are unclear
No job openings currently available and minimal public presence limits ability to assess culture, leadership, or strategic traction

Generated by Claude from Adnexus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CT-322

Glioblastoma Multiforme

Phase 1

Clinical Trials (1)

NCT00768911CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

Phase 1

CT-322

Brain and Central Nervous System Tumors

Phase 2

Clinical Trials (1)

NCT00562419CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 3 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Marketed

Pipeline